Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iPSC-Exo for pediatric moderate to severe ARDS (Phase 2, China)
ChiCTR2500097485Phase 2Not yet recruiting
- Sponsor
- Capital Institute of Pediatrics
- Start
- Feb 2025
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2 trial of iPSC-Exo in acute respiratory distress syndrome (ARDS) (2 arms), sponsored by Capital Institute of Pediatrics. Primary endpoint: Changes in oxygenation index from baseline to day 7. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
iPSC-Exo
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on ChiCTR2500097485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097485.